New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 by William New, Intellectual Property Watch Leave a Comment A ground-breaking new high-tech system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients.
WHO Board Sceptical On Changes To Global Flu Framework, Sends Issue To WHA 04/02/2019 by Catherine Saez, Intellectual Property Watch 3 Comments The World Health Organization Executive Board last week remained uncertain on the way forward on questions of access to influenza viruses as countries are increasingly implementing an international protocol regulating the sharing of genetic resources. The Board requested informal discussions be held in the lead-up to the annual World Health Assembly in May.
WHO Governance Questioned As It Adds World Health Assembly Agenda Item On Biodiversity 01/02/2019 by Catherine Saez, Intellectual Property Watch 3 Comments The World Health Organization today admitted to an unusual procedure to set up a debate on the health implications of a UN treaty on sharing of benefits from genetic resources. The new agenda item proposed by the WHO director general was accepted by the WHO Board today, but with member states questioning the governance of the move.
Current R&D Causes High Prices In Drugs; New Model Needed To Make Drugs More Affordable, Speakers Say 01/02/2019 by Sinfah Tunsarawuth for Intellectual Property Watch Leave a Comment BANGKOK – The current research and development model may encourage innovation in medicines, but has caused drugs to become unaffordable and inaccessible for people, particularly those in low- and middle-income countries, panellists and participants at a major conference here said.
Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 by Catherine Saez, Intellectual Property Watch Leave a Comment Shortages, faulty supply chains, unbearable prices, weak health systems – the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly.
WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 by David Branigan, Intellectual Property Watch Leave a Comment A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs.
WHO Draft Resolution On Universal Health Coverage Shows Efforts At Consensus 28/01/2019 by Catherine Saez, Intellectual Property Watch 2 Comments With half the world’s population still lacking access to essential health services, World Health Organization Executive Board members this week are working to agree on a resolution indicating ways through which this situation can be alleviated. Discussions are going on outside plenary room as delegates seek agreement on a draft resolution.
Open Access Advocates See End Of US Copyright Term Extension Act As Win For Commons 25/01/2019 by David Branigan, Intellectual Property Watch 1 Comment Open access advocates in the United States are celebrating the expiration, and non-renewal, of the Copyright Term Extension Act, which introduces into the public domain all works from 1923, and signals an end of the practice by US lawmakers to continually extend the terms of copyright protection. Leading figures from groups such as Creative Commons and Wikimedia Foundation gathered to discuss why this shift in policy took place, and what it means for the public domain. They asserted that this change is the result of a general acceptance of the value of “the commons,” brought on in part by the era of the internet.
US Complaints About Technology Transfer In China: Negotiating The Endgame 24/01/2019 by Intellectual Property Watch 2 Comments Dean Pinkert writes: The United States Trade Representative (USTR) has been open about its view of the difficulties faced by US companies who claim – generally anonymously – that they have been forced to transfer technology to Chinese entities: “The fact that China systematically implements its technology transfer regime in informal and indirect ways makes it ‘just as effective [as written requirements], but almost impossible to prosecute.’” As I explain in this article, I believe such informality is not merely a barrier to prosecutions; it also presents conceptual challenges for US trade negotiators as they attempt to craft effective means to address the concerns of US companies doing business in China.
US IP Law – Big Developments On The Horizon In 2019 23/01/2019 by Steven Seidenberg for Intellectual Property Watch Leave a Comment The US started 2019 with a bang. Its Supreme Court has just announced a major patent decision, and more big developments could arrive in the coming months. Here are some of the top issues to watch this year.